Nanoform Interim Report January – March (Q1) 2021
Company Announcement Nanoform Finland Plc May 27, 2021 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform Interim Report January – March (Q1) 2021 Strong momentum continues: three new non-GMP lines commissioned, four new clients signed, and six new customer PoC projects commenced. In addition, positive results from first clinical study announced, two near-term business targets achieved (“First Biologics PoC in 2021” and “at least three new non-GMP lines in 2021”), next generation STARMAP[®] launched, EUR 40 million successfully raised and commercial teams in the US